KURA

Business Context and Reporting Period

This Form 8-K Current Report from Kura Oncology, Inc. covers events occurring on May 12, 2016, specifically the Company's Annual Meeting of Stockholders. The filing details corporate governance amendments and the results of shareholder votes.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.

Material Changes and Voting Results

On May 12, 2016, stockholders approved significant amendments to the Company's governance structure:

• Director Removal: Stockholders approved an amendment to the Amended and Restated Certificate of Incorporation and Bylaws allowing any director or the entire Board to be removed, with or without cause, by holders of a majority of common stock entitled to vote.
• Shareholder Participation: As of the March 17, 2016 record date, 21,370,560 shares were outstanding. 18,598,009 shares were present or represented by proxy at the meeting.

Voting Outcomes

Guidance, Outlook, and Risks

The filing text does not provide a clear value for financial guidance, management outlook, or specific risk factors. The document serves as a record of the Annual Meeting proceedings and the filing of amended corporate documents with the Delaware Secretary of State.

Investor Verification Checklist

• Verify the full text of the Amended and Restated Certificate of Incorporation (Exhibit 3.1) and Bylaws (Exhibit 3.2) to understand the specific mechanics of the new director removal provisions.
• Confirm the tenure of the newly elected directors (Troy E. Wilson, Faheem Hasnain, Robert E. Hoffman, and Thomas Malley) through the 2017 Annual Meeting.
• Review subsequent filings for any financial updates, as this 8-K contains no financial data.